Polarityte (RGTPQ) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 09, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-32404
Entity Registrant Name	POLARITYTE, INC.
Entity Central Index Key	0001076682
Entity Tax Identification Number	06-1529524
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1960 S. 4250 West
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84104
City Area Code	(800)
Local Phone Number	560-3983
Title of 12(b) Security	Common Stock, Par Value $0.001
Trading Symbol	PTE
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		7,376,231

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 6,394	$ 11,446
Assets held for sale	338	700
Prepaid expenses and other current assets	2,195	1,109
Total current assets	8,927	13,255
Property and equipment, net	1,627	1,775
Operating lease right-of-use assets	6,584	6,906
Other assets	911	911
TOTAL ASSETS	18,049	22,847
Current liabilities
Accounts payable and accrued expenses	1,714	1,380
Other current liabilities	458	687
Total current liabilities	2,172	2,067
Common stock warrant liability	961	1,489
Operating lease liabilities	2,495	2,632
Finance lease liabilities		41
Total liabilities	5,628	6,229
STOCKHOLDERS’ EQUITY
Preferred stock – 25,000,000 shares authorized, 0 shares issued and outstanding at March 31, 2023 and December 31, 2022
Common stock – $.001 par value; 250,000,000 shares authorized; 7,325,006 and 7,258,186 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	7	7
Additional paid-in capital	532,888	532,842
Accumulated deficit	(520,474)	(516,231)
Total stockholders’ equity	12,421	16,618
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 18,049	$ 22,847

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	7,325,006	7,258,186
Common stock, shares outstanding	7,325,006	7,258,186

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net revenues
Total net revenues		$ 741
Cost of revenues
Total costs of revenues		491
Gross profit		250
Operating costs and expenses
Research and development	2,282	2,860
General and administrative	2,464	6,209
Impairment of assets held for sale	56	54
Total operating costs and expenses	4,802	9,123
Operating loss	(4,802)	(8,873)
Other income (expense), net
Change in fair value of common stock warrant liability	528	5,105
Interest expense, net	31	(15)
Other income, net		12
Net loss and comprehensive loss	$ (4,243)	$ (3,771)
Net loss per share attributable to common stockholders
Basic	$ (0.58)	$ (1.12)	[1]
Diluted	$ (0.58)	$ (2.37)	[1]
Weighted average shares outstanding
Basic	7,320,754	3,364,535	[1]
Diluted	7,320,754	3,575,970	[1]
Service [Member]
Net revenues
Total net revenues		$ 741
Cost of revenues
Total costs of revenues		$ 491
[1]Giving retroactive effect to the 1-for-25

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	May 16, 2022	May 12, 2022
Income Statement [Abstract]
Reverse stock split	1-for-25	1-for-25 (“Reverse Stock Split”)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands		Preferred Stock [Member] Convertible Preferred Stock [Member]	Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021			$ 3		$ 527,639	$ (508,398)	$ 19,244
Balance, shares at Dec. 31, 2021			3,299,379	[1]
Stock-based compensation expense					762		762
Vesting of restricted stock units
Vesting of restricted stock units, shares	[1]		25,676
Net loss						(3,771)	(3,771)
Issuance of preferred stock and warrants through underwritten offering, net of issuance costs of $184					1,685		1,685
Issuance of preferred stock and warrants through underwritten offering, net of issuance costs of $184, shares		5,000
Issuance of common stock upon conversion of preferred stock			$ 1		(1)
Issuance of common stock upon conversion of preferred stock, shares		(5,000)	655,738	[1]
Shares withheld for tax withholding					(127)		(127)
Shares withheld for tax withholding, shares	[1]		(7,402)
Balance at Mar. 31, 2022			$ 4		529,958	(512,169)	17,793
Balance, shares at Mar. 31, 2022			3,973,391	[1]
Balance at Dec. 31, 2022			$ 7		532,842	(516,231)	16,618
Balance, shares at Dec. 31, 2022			7,258,186	[1]
Stock-based compensation expense					46		46
Vesting of restricted stock units
Vesting of restricted stock units, shares	[1]		66,820
Net loss						(4,243)	(4,243)
Balance at Mar. 31, 2023			$ 7		$ 532,888	$ (520,474)	$ 12,421
Balance, shares at Mar. 31, 2023			7,325,006	[1]
[1]Giving retroactive effect to the 1-for-25

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) (Parenthetical) $ in Thousands	Mar. 31, 2022 USD ($)
Underwritten Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Debt issuance costs, net	$ 184

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,243)	$ (3,771)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	46	762
Depreciation and amortization	148	455
Impairment of assets held for sale	56	54
Change in fair value of common stock warrant liability	(528)	(5,105)
Gain on finance lease termination	(61)
Net (gain)/loss on sale of property and equipment and held for sale assets	31	(2)
Changes in operating assets and liabilities:
Accounts receivable		256
Prepaid expenses and other current assets	(1,086)	(393)
Operating lease right-of-use assets	322	292
Accounts payable and accrued expenses	352	1,702
Other current liabilities	1	(1)
Deferred revenue		(52)
Operating lease liabilities	(118)	(238)
Net cash used in operating activities	(5,080)	(6,041)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(31)
Proceeds from sale of property and equipment and held for sale assets	100	7
Net cash provided by/(used in) investing activities	100	(24)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from insurance financing arrangements		1,027
Principal payments on term note payable and financing arrangements		(10)
Principal payments on financing leases	(72)	(116)
Net proceeds from the sale of preferred stock and warrants		4,814
Cash paid for tax withholdings related to net share settlement		(127)
Net cash provided by/(used in) financing activities	(72)	5,588
Net decrease in cash and cash equivalents, including cash classified within assets held for sale	(5,052)	(477)
Less: net increase in cash and cash equivalents classified within assets held for sale		175
Net decrease in cash and cash equivalents	(5,052)	(652)
Cash and cash equivalents - beginning of period	11,446	19,375
Cash and cash equivalents - end of period	6,394	18,723
Supplemental cash flow information:
Cash paid for interest	7	16
Supplemental schedule of non-cash investing and financing activities:
Disposal of held for sale assets in exchange for extinguishment of finance lease liabilities	157
Fair value of placement agent warrants issued in connection with offerings		144
Conversion of Series A and Series B preferred stock into common stock		16
Allocation of proceeds to warrant liability		3,129
Deferred and accrued offering costs		104
Reclassification of assets held for sale		3,163
Reclassification of liabilities held for sale		$ 215

PRINCIPAL BUSINESS ACTIVITY AND

PRINCIPAL BUSINESS ACTIVITY AND BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
PRINCIPAL BUSINESS ACTIVITY AND BASIS OF PRESENTATION	1. PRINCIPAL BUSINESS ACTIVITY AND BASIS OF PRESENTATION PolarityTE, Inc. (together with its subsidiaries, the “Company”) is a clinical stage biotechnology company developing regenerative tissue products and biomaterials. The Company also operated a laboratory testing and clinical research business until the end of April 2022. The Company’s first regenerative tissue product is SkinTE. In July 2021, the Company submitted an investigational new drug application (“IND”) for SkinTE to the United States Food and Drug Administration (the “FDA”) through its subsidiary, PolarityTE MD, Inc. Prior to June 1, 2021, the Company sold SkinTE under Section 361 of the Public Health Service Act in 2020 and into 2021 and, after the Company’s decision to file an IND under Section 351 of that Act, under an enforcement discretion position stated by the FDA in a regenerative medicine policy framework to help facilitate regenerative medicine therapies. The FDA’s stated period of enforcement discretion ended May 31, 2021. Consequently, the Company terminated commercial sales of SkinTE on May 31, 2021, ceased its SkinTE commercial operations, and has transitioned to a clinical stage company pursuing an IND for SkinTE. As a result, there are no product sales from commercial SkinTE after June 2021. At the beginning of May 2018, the Company acquired a preclinical research and veterinary sciences business, which had been used for preclinical studies on the Company’s regenerative tissue products and to offer preclinical research services to unrelated third parties on a contract basis. The Company sold the business at the end of April 2022 and ceased to recognize services revenues after the sale. Consequently, the Company is no longer engaged in any revenue generating business activity and its operations are now focused on advancing the IND for SkinTE. The accompanying interim condensed consolidated financial statements of the Company are unaudited, but in the opinion of management, reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the results for the interim periods presented. Accordingly, they do not include all information and notes required by accounting principles generally accepted in the United States of America (U.S. GAAP) for complete financial statements. The results of operations for interim periods are not necessarily indicative of results to be expected for the entire fiscal year. The balance sheet at December 31, 2022, has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2022, filed with the Securities and Exchange Commission on Form 10-K on March 27, 2023.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation Use of estimates Concentration of Credit Risk 250,000 Assets and Liabilities Held for Sale 0.1 Leases The Company has lease agreements with lease and non-lease components. As allowed under ASC 842, the Company has elected not to separate lease and non-lease components for any leases involving real estate and office equipment classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement of ASC 842 to leases with a term of 12 months or less for all classes of assets. Impairment of Long-Lived Assets Revenue Recognition The Company does not currently perform any revenue generating activities. Prior to the sale of IBEX Preclinical Research, Inc. (“IBEX”) in April 2022, the Company recorded service revenues from the sale of its preclinical research services, which included delivery of preclinical studies and other research services to unrelated third parties. Service revenues generally consisted of a single performance obligation that the Company satisfied over time using an input method based on costs incurred to date relative to the total costs expected to be required to satisfy the performance obligation. See Note 5 for further details on the IBEX sale. Research and Development Expenses Accruals for Clinical Trials Common Stock Warrant Liability Stock-Based Compensation The fair value for options issued is estimated at the date of grant using a Black-Scholes option-pricing model. The risk-free rate is derived from the U.S. Treasury yield curve in effect at the time of the grant commensurate with the expected term of the option The fair value of restricted stock grants is measured based on the fair market value of the Company’s common stock on the date of grant and recognized as compensation expense over the vesting period of, generally, six months to three years. Reverse Stock Split 1-for-25 (“Reverse Stock Split”) 17,024 The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260 Earnings Per Share Net Loss Per Share Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. All common stock warrants issued participate on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors, on the Company’s common stock. For purposes of computing earnings per share (EPS), outstanding warrants and preferred stock are considered to participate with common stock in earnings of the Company. Therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net loss for the period is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed losses. No loss was allocated to the warrants or preferred stock for the three months ended March 31, 2023 and 2022 as the Company incurred a loss for each period and the warrant and preferred stockholders are not required to absorb losses. The Company has issued pre-funded warrants from time to time at an exercise price of $ 0.025 Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses (Topic 326) Financial Instruments–Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates

LIQUIDITY AND GOING CONCERN

LIQUIDITY AND GOING CONCERN	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY AND GOING CONCERN	3. LIQUIDITY AND GOING CONCERN The Company is a clinical stage biotechnology company that has incurred recurring losses and negative cash flows from operations since commencing its biotechnology business in 2017. As of March 31, 2023, the Company had an accumulated deficit of $ 520.5 6.4 These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and settle its liabilities in the normal course of business. The Company’s significant operating losses raise substantial doubt regarding the Company’s ability to continue as a going concern for at least one year from the date of issuance of these condensed consolidated financial statements. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. Consequently, the future success of the Company depends on its ability to attract additional capital and, ultimately, on its ability to successfully complete the regulatory approval process for its product, SkinTE, and develop future profitable operations. The Company will seek additional capital through equity offerings or debt financing. However, such financing may not be available in the future on favorable terms, if at all.

FAIR VALUE

FAIR VALUE	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE	4. FAIR VALUE In accordance with ASC 820, Fair Value Measurements and Disclosures ● Level 1: Observable inputs such as quoted prices in active markets for identical instruments. ● Level 2: Quoted prices for similar instruments that are directly or indirectly observable in the market. ● Level 3: Significant unobservable inputs supported by little or no market activity. Financial instruments whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques, for which determination of fair value requires significant judgment or estimation. Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. There were no transfers within the hierarchy for any of the periods presented. The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands): SCHEDULE OF FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES MEASURES ON RECURRING BASIS March 31, 2023 Level 1 Level 2 Level 3 Total Liabilities Common stock warrant liability $ – $ – $ 961 $ 961 Total $ – $ – $ 961 $ 961 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Common stock warrant liability $ – $ – $ 1,489 $ 1,489 Total $ – $ – $ 1,489 $ 1,489 The Company assesses its assets held for sale, long-lived assets, including property, equipment, and ROU assets at their estimated fair value on a non-recurring basis. The Company reviews the carrying amounts of such assets when events indicate that their carrying amounts may not be recoverable. Any resulting impairment would require that the asset be recorded at its fair value. During each of the three months ended March 31, 2023 and 2022, the Company recognized an impairment charge of $ 0.1 The following table presents the change in fair value of the liability classified common stock warrants for the three months ended March 31, 2023 (in thousands): SCHEDULE OF FAIR VALUE OF LIABILITY CLASSIFIED COMMON STOCK WARRANTS Fair Value at December 31, 2022 (Gain) Loss Upon Change in Fair Value Fair Value at March 31, 2023 Warrant liabilities February 14, 2020 issuance $ 8 $ (2 ) $ 6 December 23, 2020 issuance 2 (1 ) 1 January 14, 2021 issuance 72 (42 ) 30 January 25, 2021 issuance 64 (37 ) 27 March 16, 2022 issuance 26 (25 ) 1 June 8, 2022 issuance 1,317 (421 ) 896 Total $ 1,489 $ (528 ) $ 961 The following table presents the change in fair value of the liability classified common stock warrants for the three months ended March 31, 2022 (in thousands): Fair Value at December 31, 2021 Initial Fair Value at Issuance (Gain) Loss Upon Change in Fair Value Fair Value at March 31, 2022 Warrant liabilities February 14, 2020 issuance $ 291 $ – $ (179 ) $ 112 December 23, 2020 issuance 239 – (166 ) 73 January 14, 2021 issuance 3,345 – (1,856 ) 1,489 January 25, 2021 issuance 2,969 – (1,649 ) 1,320 March 16, 2022 issuance – 3,129 (1,255 ) 1,874 Total $ 6,844 $ 3,129 $ (5,105 ) $ 4,868 The Company uses the Monte Carlo simulation model to determine the fair value of the liability classified warrants. Input assumptions used to measure the fair value of these freestanding instruments are as follows: SCHEDULE OF FAIR VALUE ASSUMPTIONS OF WARRANTS LIABILITY For the Three Months ended March 31, 2023 Stock price $ 0.50 0.50 Exercise price $ 2.40 34.38 Risk-free rate 3.68 4.66 % Volatility 107.0 113.1 % Remaining term (years) 0.96 4.19 For the Three Months ended March 31, 2022 Stock price $ 6.25 8.50 Exercise price $ 2.50 34.50 Risk-free rate 1.95 2.44 % Volatility 98.4 103.6 % Remaining term (years) 1.96 4.87

ASSETS AND LIABILITIES HELD FOR

ASSETS AND LIABILITIES HELD FOR SALE	3 Months Ended
	Mar. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
ASSETS AND LIABILITIES HELD FOR SALE	5. ASSETS AND LIABILITIES HELD FOR SALE Equipment The Company committed to a plan to sell a variety of lab equipment within the regenerative medicine products reporting segment. The lab equipment has been designated as held for sale and is presented as such within the condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022. During each of the three months ended March 31, 2023 and 2022, the Company recorded an impairment of $ 0.1 IBEX Sale At the beginning of May 2018, the Company acquired a preclinical research and veterinary sciences business, which has been used for preclinical studies on the Company’s regenerative tissue products and to offer preclinical research services to unrelated third parties on a contract basis. The Company operated this business through its indirect subsidiary, IBEX Preclinical Research, Inc. (“IBEX”). Utah CRO Services, Inc., a Nevada corporation (“Utah CRO”), is a direct subsidiary of the Company and held all the outstanding capital stock of IBEX (the “IBEX Shares”). Utah CRO also holds all the member interest of IBEX Property LLC, a Nevada limited liability company (“IBEX Property”), that owned two unencumbered parcels of real property in Logan, Utah, consisting of approximately 1.75 In March 2022, the Company reached a nonbinding understanding with an unrelated third party that contemplated the sale of IBEX, which operates within the contract services reporting segment, along with IBEX Property. The assets and liabilities related to IBEX were designated as held for sale. The Company measured the assets and liabilities held for sale at the lower of their carrying value or fair value less costs to sell. The operating results of IBEX did not qualify for reporting as discontinued operations. On April 14, 2022, Utah CRO entered into a Stock Purchase Agreement (the “Stock Agreement”) with an unrelated third party (“Buyer”), pursuant to which Utah CRO agreed to sell all the outstanding IBEX Shares to Buyer in exchange for an unsecured promissory note in the principal amount of $ 0.4 10 five-year 2.8 0.4 2.3 0.4

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	3 Months Ended
	Mar. 31, 2023
Prepaid Expenses And Other Current Assets
PREPAID EXPENSES AND OTHER CURRENT ASSETS	6. PREPAID EXPENSES AND OTHER CURRENT ASSETS The following table presents the major components of prepaid expenses and other current assets (in thousands): SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2023 December 31, 2022 Prepaid insurance $ 1,249 $ 239 Other current receivable 446 332 Prepaid expenses 402 440 Deferred offering costs 98 98 Total prepaid expenses and other current assets $ 2,195 $ 1,109

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	7. PROPERTY AND EQUIPMENT, NET The following table presents the components of property and equipment, net (in thousands): SCHEDULE OF PROPERTY AND EQUIPMENT, NET March 31, 2023 December 31, 2022 Machinery and equipment $ 4,436 $ 4,436 Computers and software 570 570 Leasehold improvements 1,808 1,808 Furniture and equipment 100 100 Total property and equipment, gross 6,914 6,914 Accumulated depreciation (5,287 ) (5,139 ) Total property and equipment, net $ 1,627 $ 1,775 Depreciation and amortization expense for property and equipment, including assets acquired under financing leases was as follows (in thousands): SCHEDULE OF DEPRECIATION AND AMORTIZATION EXPENSE For the Three Months Ended March 31, 2023 2022 General and administrative expense $ 3 $ 49 Research and development expense 145 406 Total depreciation and amortization expense $ 148 $ 455

LEASES

LEASES	3 Months Ended
	Mar. 31, 2023
Leases
LEASES	8. LEASES The Company leases facilities and certain equipment under noncancelable leases that expire at various dates through November 2027. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases may include options to extend or terminate the lease at the election of the Company. These optional periods have not been considered in the determination of the right-of-use-assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. Operating Leases In November 2022, the Company entered into an operating lease for approximately 63,156 The initial term of the lease is five years November 30, 2027 The Company has a one-time option to renew for an additional five years The initial base rent under this lease is $ 59,998 4.0 10 In November 2021, the Company entered into an operating lease to obtain office equipment with Pacific Office Automation, Inc. The initial term of the lease is three years The initial base rent under this lease is $ 3,983 0.1 7.42 Financing Leases In November 2018 and April 2019, the Company entered into financing leases primarily for laboratory equipment used in research and development activities. The financing leases have remaining terms that range from 3 8 10 In March 2023, the Company negotiated a buyout of a financing lease liability of $ 0.2 0.1 As of March 31, 2023, the maturities of operating and finance lease liabilities were as follows (in thousands): SCHEDULE OF OPERATING AND FINANCE LEASE LIABILITIES Operating leases * Finance leases 2023 (excluding the three months ended March 31, 2023) $ 478 $ 45 2024 793 – 2025 781 – 2026 813 – 2027 772 – Total lease payments 3,637 45 Less: Imputed interest (729 ) (1 ) Total $ 2,908 $ 44 * 2023 amounts shown above are net of cash inflows for tenant improvement allowances expected to be received during the year. Supplemental balance sheet information related to leases was as follows (in thousands): Finance leases SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO FINANCE AND OPERATING LEASES March 31, 2023 December 31, 2022 Finance lease right-of-use assets included within property and equipment, net $ 4 $ 4 Current finance lease liabilities included within other current liabilities $ 45 $ 293 Non-current finance lease liabilities included within other long-term liabilities – 41 Total $ 45 $ 334 Operating leases March 31, 2023 December 31, 2022 Current operating lease liabilities included within other current liabilities $ 413 $ 394 Operating lease liabilities – non-current 2,495 2,632 Total $ 2,908 $ 3,026 The components of lease expense were as follows (in thousands): SUMMARY OF COMPONENT OF LEASE EXPENSE 2023 2022 For the Three Months Ended March 31, 2023 2022 Operating lease costs included within operating costs and expenses $ 395 $ 318 Finance lease costs: Amortization of right-of-use assets $ – $ 51 Interest on lease liabilities 7 16 Total $ 7 $ 67 Supplemental cash flow information related to leases was as follows (in thousands): SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES 2023 2022 For the Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash out flows from operating leases $ 192 $ 264 Operating cash out flows from finance leases $ 7 $ 16 Financing cash out flows from finance leases $ 72 $ 116 As of March 31, 2023 and December 31, 2022, the weighted average remaining lease term for operating leases was 4.6 4.8 9.70 9.69 0.7 1.2 8.25 9.67

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES The following table presents the major components of accounts payable and accrued expenses (in thousands): SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES March 31, 2023 December 31, 2022 Accounts payable $ 244 $ 459 Salaries and other compensation 517 463 Legal and accounting 264 71 Accrued severance 63 16 Benefit plan accrual 66 66 Clinical trials 369 131 Other 191 174 Total accounts payable and accrued expenses $ 1,714 $ 1,380

OTHER CURRENT LIABILITIES

OTHER CURRENT LIABILITIES	3 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
OTHER CURRENT LIABILITIES	10. OTHER CURRENT LIABILITIES The following table presents the major components of other current liabilities (in thousands): SCHEDULE OF OTHER CURRENT LIABILITIES March 31, 2023 December 31, 2022 Current finance lease liabilities $ 45 $ 293 Current operating lease liabilities 413 394 Total other current liabilities $ 458 $ 687

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	11. STOCK-BASED COMPENSATION 2020, 2019 and 2017 Equity Incentive Plans 2020 Plan On October 25, 2019, the Company’s Board of Directors (the “Board”) approved the Company’s 2020 Stock Option and Incentive Plan (the “2020 Plan”). The 2020 Plan became effective on December 19, 2019, the date approved by the stockholders. The 2020 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, unrestricted stock awards, dividend equivalent rights, and cash-based awards to the Company’s employees, officers, directors, and consultants. The Board designated the Compensation Committee of the Board the administrator of the 2020 Plan, including determining which eligible participants will receive awards, the number of shares of common stock subject to the awards and the terms and conditions of such awards. Up to 419,549 December 19, 2029 131,872 1,450,000 6,357 2019 Plan On October 5, 2018, the Company’s Board approved the Company’s 2019 Equity Incentive Plan (the “2019 Plan”). The 2019 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights and other types of stock-based awards to the Company’s employees, officers, directors, and consultants. The Board designated the Compensation Committee of the Board the administrator of the 2019 Plan, including determining which eligible participants will receive awards, the number of shares of common stock subject to the awards and the terms and conditions of such awards. Up to 120,000 October 5, 2028 10,920 2017 Plan On December 1, 2016, the Company’s Board approved the Company’s 2017 Equity Incentive Plan (the “2017 Plan”). The purpose of the 2017 Plan is to promote the success of the Company and to increase stockholder value by providing an additional means through the grant of awards to attract, motivate, retain and reward selected employees, consultants and other eligible persons. The 2017 Plan provides for the grant of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights and other types of stock-based awards to the Company’s employees, officers, directors, and consultants. The Board designated the Compensation Committee of the Board the administrator of the 2017 Plan, including determining which eligible participants will receive awards, the number of shares of common stock subject to the awards and the terms and conditions of such awards. Up to 292,000 December 1, 2026 14,246 A summary of the Company’s employee and non-employee stock option activity is presented below: SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS,ACTIVITY Number of Shares Weighted-Average Exercise Price Outstanding – December 31, 2022 182,311 $ 188.50 Granted – $ – Forfeited (21,653 ) $ 163.66 Outstanding – March 31, 2023 160,658 $ 191.85 Options exercisable, March 31, 2023 158,459 $ 193.22 Employee Stock Purchase Plan (ESPP) In May 2018, the Company adopted the Employee Stock Purchase Plan (“ESPP”). The Company has initially reserved 20,000 85 5,584 Restricted Stock A summary of the Company’s employee and non-employee restricted stock activity is presented below: SCHEDULE OF SHARE-BASED COMPENSATION ,RESTRICTED STOCK ACTIVITY Number of Shares Unvested - December 31, 2022 256,435 Granted 42,986 Vested (66,820 ) Forfeited (38,483 ) Unvested – March 31, 2023 194,118 Stock-Based Compensation Expense The stock-based compensation expense related to stock options, restricted stock awards, and the employee stock purchase plan was as follows (in thousands): SCHEDULE OF SHARE-BASED COMPENSATION RELATED TO RESTRICTED STOCK AWARDS AND STOCK OPTIONS 2023 2022 For the Three Months Ended March 31, 2023 2022 General and administrative expense $ 31 $ 546 Research and development expense 15 216 Total stock-based compensation expense $ 46 $ 762

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	12. STOCKHOLDERS’ EQUITY March 2022 Offering On March 16, 2022, the Company completed a registered direct offering of 3,000.000435 2,000.00029 655,738 655,738 5.0 8.75 Concurrent with the closing of the offering on March 16, 2022, the Company modified the exercise price of the Existing 2021 Warrants. 363,636 320,641 30 8.75 The holders of Series A and Series B convertible preferred stock were entitled to receive dividend payments in the same form as dividends paid on shares of the common stock when, as and if such dividends were paid on shares of the common stock, on an if converted basis. In the event of a liquidation event, the holders of each series of convertible preferred stock were entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the preferred stock were fully converted. Each share of preferred stock was convertible at any time after the offering at the option of the holder into a number of shares of the Company’s common stock, equal to $ 1,000 7.625 262,295 393,443 The holder of the March 2022 Warrants may not exercise any portion of such warrants to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, which percentage may be changed at the holder’s election to a lower percentage at any time or to a higher percentage not to exceed 9.99% upon 61 days’ notice to the Company The Company also issued to designees of the placement agent warrants to purchase 5.0 March 2022 Warrants sold in the offering , or 32,787 , except that the placement agent warrants have an exercise price $ 9.525 125 As the March 2022 Warrants and placement agent warrants could each require cash settlement in certain scenarios, the March 2022 Warrants and placement agent warrants were classified as liabilities upon issuance and were initially recorded at estimated fair values of $ 3.0 0.1 1.9 The net proceeds to the Company from the offering were $ 4.5 0.2 0.3 and private placement common stock warrants, June 2022 Offering On June 5, 2022, the Company entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement (together with the registered direct offering, the “Offerings”), the Company entered into a separate securities purchase agreement with the same investor for the unregistered purchase and sale of shares of common stock (or pre-funded warrants in lieu thereof). On June 8, 2022, the Company completed the registered direct offering of 445,500 0.001 2.525 1,138,659 2.524 1,584,159 2.524 placement offering is exercisable for one share of common stock at an exercise price of $ 0.001 3,168,318 2.40 488,659 545,000 1,689,159 3,168,318 The holder of the warrants may not exercise any portion of such warrants to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, which percentage may be changed at the holder’s election to a lower percentage at any time or to a higher percentage not to exceed 9.99% upon 61 days’ notice to the Company. The Company also issued to designees of the placement agent, warrants to purchase 5.0% of the aggregate number of common stock shares and pre-funded warrants sold in the offering 158,416 125 3.156 7.3 0.7 As the June 2022 Warrants and placement agent common stock warrants could each require cash settlement in certain scenarios, the June 2022 Warrants and placement agent common stock warrants were classified as liabilities upon issuance and were initially recorded at estimated fair values of $ 5.7 0.3 2.0 0.2 0.5 The following table summarizes warrant activity for the three months ended March 31, 2023: SUMMARY OF WARRANT ACTIVITY Outstanding December 31, 2022 Warrants Issued Warrants Exercised Outstanding March 31, 2023 Transaction February 14, 2020 common warrants 21,580 – – 21,580 December 23, 2020 placement agent warrants 25,651 – – 25,651 January 14, 2021 common warrants 363,636 – – 363,636 January 14, 2021 placement agent warrants 21,818 – – 21,818 January 25, 2021 common warrants 320,641 – – 320,641 January 22, 2021 placement agent warrants 19,238 – – 19,238 March 16, 2022 common warrants 655,738 – – 655,738 March 16, 2022 placement agent warrants 32,787 – – 32,787 June 8, 2022 common warrants 3,168,318 – – 3,168,318 June 8, 2022 placement agent warrants 158,416 – – 158,416 Total 4,787,823 – – 4,787,823 On March 30, 2021, the Company entered into a sales agreement (“Sales Agreement”) with an investment banking firm to sell shares of common stock having aggregate sales proceeds of up to $ 50.0 0.4 0.7

NET LOSS PER SHARE ATTRIBUTABLE

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	3 Months Ended
	Mar. 31, 2023
Net loss per share attributable to common stockholders
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	13. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following tables present reconciliations for the numerators and denominators of basic and diluted net loss per share: SCHEDULE OF EARNINGS PER SHARE , BASIC AND DILUTED Numerator: 2023 2022 For the Three Months Ended March 31, March 31, Numerator: 2023 2022 Net loss, primary $ (4,243 ) $ (3,771 ) Less: gain from change in fair value of warrant liabilities – (4,694 ) Net loss, diluted $ (4,243 ) $ (8,465 ) Denominator: 2023 2022 For the Three Months Ended March 31, March 31, Denominator: 2023 2022 Basic weighted average number of common shares 7,320,754 3,364,535 Potentially dilutive effect of warrants – 211,435 Diluted weighted average number of common shares 7,320,754 3,575,970 The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: SCHEDULE OF ANTI-DILUTIVE POTENTIAL SHARES OUTSTANDING ACTIVITY 2023 2022 For the Three Months Ended March 31, March 31, 2023 2022 Stock options 160,658 212,428 Restricted stock 194,118 174,054 Common stock warrants 4,787,823 66,708 Shares committed under ESPP 5,584 1,923 Outstanding potentially dilutive securities 5,584 1,923

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	14. COMMITMENTS AND CONTINGENCIES Contingencies Securities Class Action and Derivative Lawsuits On September 24, 2021, a class action complaint alleging violations of the Federal securities laws was filed in the United States District Court, District of Utah, by Marc Richfield against the Company and certain officers of the Company, Case No. 2:21-cv-00561-BSJ. The Court subsequently appointed a Lead Plaintiff and ordered the Lead Plaintiff to file an amended Complaint by February 7, 2022, which was extended to February 21, 2022. The Lead Plaintiff filed an amended complaint on February 21, 2022, against the Company, two current officers of the Company, and three former officers of the Company (the “Complaint”). The Complaint alleges that during the period from January 30, 2018, through November 9, 2021, the defendants made or were responsible for, disseminating information to the public through reports filed with the Securities and Exchange Commission and other channels that contained material misstatements or omissions in violation of Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934, as amended, and Rule 10b-5 adopted thereunder. Specifically, the Complaint alleges that the defendants misrepresented or failed to disclose that: (i) the Company’s product, SkinTE, was improperly registered as a 361 HCT/P under Section 361 of the Public Health Service Act and that, as a result, the Company’s ability to commercialize SkinTE as a 361 HCT/P was not sustainable because it was inevitable SkinTE would need to be registered under Section 351 of the Public Health Service Act; (ii) the Company characterized itself as a commercial stage company when it knew sales of SkinTE as a 361 HCT/P were unsustainable and that, as a result, it would need to file an IND and become a development stage company; (iii) issues arising from an FDA inspection of the Company’s facility in July 2018, were not resolved even though the Company stated they were resolved; and (iv) the IND for SkinTE was deficient with respect to certain chemistry, manufacturing, and control items, including items identified by the FDA in July 2018, and as a result it was unlikely that the FDA would approve the IND in the form it was originally filed. The Company filed a motion to dismiss the complaint for failure to state a claim, on April 22, 2022. The Lead Plaintiff filed its memorandum in opposition to the Company’s motion to dismiss on July 18, 2022. The Company filed its reply memorandum to the Lead Plaintiff’s opposition memorandum on August 11, 2022, and oral argument on the motion to dismiss was held September 8, 2022. At the hearing the judge issued a ruling from the bench dismissing the Complaint without prejudice and granting the Lead Plaintiff leave to file an amended complaint. The Lead Plaintiff filed an amended complaint (the “Amended Complaint”) on October 3, 2022, alleging additional facts. The Company filed a motion to dismiss the Amended Complaint for failure to state a claim on November 2, 2022, Lead Plaintiff filed its brief in opposition to the Company’s motion on December 2, 2022, and the Company filed its reply brief to the Lead Plaintiff brief in opposition on December 23, 2022. Oral argument on the Company’s motion to dismiss the Amended Complaint was held March 6, 2023. Following oral argument, the judge ruled that the Amended Complaint be dismissed with prejudice and requested that the Company, through its counsel, submit a proposed opinion and order. The Company and Lead Plaintiff subsequently reached an agreement stipulating to the form of the opinion and order, waiving the Lead Plaintiff’s right to appeal, and waiving the Company’s right to seek sanctions under Rule 11 of the Federal Rules of Civil Procedure. The final opinion and order dismissing the Amended Complaint with prejudice was issued by the judge on April 19, 2023. On October 25, 2021, a stockholder derivative complaint alleging violations of the Federal securities laws was filed in the United States District Court, District of Utah, by Steven Battams against the Company, each member of the Board of directors, and two officers of the Company, Case No. 2:21-cv-00632-DBB (the “Stockholder Derivative Complaint”). The Stockholder Derivative Complaint alleges that the defendants made, or were responsible for, disseminating information to the public through reports filed with the Securities and Exchange Commission and other channels that contained material misstatements or omissions in violation of Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934, as amended, and Rule 10b-5 adopted thereunder. Specifically, the Stockholder Derivative Complaint alleges that the defendants misrepresented or failed to disclose that: (i) the IND for the Company’s product, SkinTE, filed with the FDA was deficient with respect to certain chemistry, manufacturing, and control items; (ii) as a result, it was unlikely that the FDA would approve the IND in its current form; (iii) accordingly, the Company had materially overstated the likelihood that the SkinTE IND would obtain FDA approval; and (iv) as a result, the public statements regarding the IND were materially false and misleading. The parties have stipulated to stay the Stockholder Derivative Complaint until (1) the dismissal of the Complaint described above, (2) denial of a motion to dismiss the Complaint, or (3) notice is given that any party is withdrawing its consent to the stipulated stay of the Stockholder Derivative Complaint proceeding. After the order of dismissal with prejudice of the class action lawsuit described above and exhaustion of all appeals by the Lead Plaintiff, the stay of the Stockholder Derivative Complaint will expire. The Company believes the allegations in the Stockholder Derivative Complaint are without merit and intends to defend the litigation vigorously after the stay expires. At this early stage of the proceedings the Company is unable to make any prediction regarding the outcome of the litigation. Other Matters In the ordinary course of business, the Company may become involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to intellectual property, commercial arrangements, employment, regulatory compliance, and other matters. Except as noted above, at March 31, 2023, the Company was not party to any legal or arbitration proceedings that may have significant effects on its financial position or results of operations. No governmental proceedings are pending or, to the Company’s knowledge, contemplated against the Company. The Company is not a party to any material proceedings in which any director, member of senior management or affiliate of the Company’s is either a party adverse to the Company or its subsidiaries or has a material interest adverse to the Company or its subsidiaries. Commitments The Company has entered into employment agreements with key executives that contain severance terms and change of control provisions. On June 25, 2021, the Company entered into a statement of work with a contract research organization to provide services for a proposed clinical trial described as a multi-center, prospective, randomized controlled trial evaluating the effects of SkinTE in the treatment of full-thickness diabetic foot ulcers at a cost of approximately $ 6.5 3.1 3.4 0.5 0.4 0.2

SEGMENT REPORTING

SEGMENT REPORTING	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
SEGMENT REPORTING	15. SEGMENT REPORTING Reportable segments are presented in a manner consistent with the internal reporting provided to the chief operating decision maker (CODM), the Chief Executive Officer of the Company. The CODM allocates resources to and assesses the performance of each segment using information about its revenue and operating income (loss). The Company’s operations involve products and services which are managed separately. Accordingly, it operates in two segments: 1) regenerative medicine products and 2) contract services. In April 2022, the Company sold IBEX and IBEX Property, the Company’s subsidiaries which operate within the contract services reporting segment. Contract services ceased to be a reportable segment upon disposal of IBEX and historical information from prior to the disposal date is reported here. See Note 5 for detail on management’s disposal of IBEX. Certain information concerning the Company’s segments is presented in the following tables (in thousands): SCHEDULE OF SEGMENT INFORMATION 2023 2022 For the Three Months Ended March 31, 2023 2022 Net revenues: Reportable segments: Regenerative medicine $ — $ — Contract services — 741 Total net revenues $ — $ 741 Net (loss)/income: Reportable segments: Regenerative medicine $ (4,243 ) $ (3,545 ) Contract services — (226 ) Total net loss $ (4,243 ) $ (3,771 )

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
Use of estimates	Use of estimates
Concentration of Credit Risk	Concentration of Credit Risk 250,000
Assets and Liabilities Held for Sale	Assets and Liabilities Held for Sale 0.1
Leases	Leases The Company has lease agreements with lease and non-lease components. As allowed under ASC 842, the Company has elected not to separate lease and non-lease components for any leases involving real estate and office equipment classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company has also elected not to apply the recognition requirement of ASC 842 to leases with a term of 12 months or less for all classes of assets.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
Revenue Recognition	Revenue Recognition The Company does not currently perform any revenue generating activities. Prior to the sale of IBEX Preclinical Research, Inc. (“IBEX”) in April 2022, the Company recorded service revenues from the sale of its preclinical research services, which included delivery of preclinical studies and other research services to unrelated third parties. Service revenues generally consisted of a single performance obligation that the Company satisfied over time using an input method based on costs incurred to date relative to the total costs expected to be required to satisfy the performance obligation. See Note 5 for further details on the IBEX sale.
Research and Development Expenses	Research and Development Expenses
Accruals for Clinical Trials	Accruals for Clinical Trials
Common Stock Warrant Liability	Common Stock Warrant Liability
Stock-Based Compensation	Stock-Based Compensation The fair value for options issued is estimated at the date of grant using a Black-Scholes option-pricing model. The risk-free rate is derived from the U.S. Treasury yield curve in effect at the time of the grant commensurate with the expected term of the option The fair value of restricted stock grants is measured based on the fair market value of the Company’s common stock on the date of grant and recognized as compensation expense over the vesting period of, generally, six months to three years.
Reverse Stock Split	Reverse Stock Split 1-for-25 (“Reverse Stock Split”) 17,024 The Company accounted for the reverse stock split on a retrospective basis pursuant to ASC 260 Earnings Per Share
Net Loss Per Share	Net Loss Per Share Gains on warrant liabilities are only considered dilutive when the average market price of the common stock during the period exceeds the exercise price of the warrants. All common stock warrants issued participate on a one-for-one basis with common stock in the distribution of dividends, if and when declared by the Board of Directors, on the Company’s common stock. For purposes of computing earnings per share (EPS), outstanding warrants and preferred stock are considered to participate with common stock in earnings of the Company. Therefore, the Company calculates basic and diluted EPS using the two-class method. Under the two-class method, net loss for the period is allocated between common stockholders and participating securities according to dividends declared and participation rights in undistributed losses. No loss was allocated to the warrants or preferred stock for the three months ended March 31, 2023 and 2022 as the Company incurred a loss for each period and the warrant and preferred stockholders are not required to absorb losses. The Company has issued pre-funded warrants from time to time at an exercise price of $ 0.025
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments-Credit Losses (Topic 326) Financial Instruments–Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates

FAIR VALUE (Tables)

FAIR VALUE (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
SCHEDULE OF FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES MEASURES ON RECURRING BASIS	The following table sets forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands): SCHEDULE OF FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES MEASURES ON RECURRING BASIS March 31, 2023 Level 1 Level 2 Level 3 Total Liabilities Common stock warrant liability $ – $ – $ 961 $ 961 Total $ – $ – $ 961 $ 961 December 31, 2022 Level 1 Level 2 Level 3 Total Liabilities Common stock warrant liability $ – $ – $ 1,489 $ 1,489 Total $ – $ – $ 1,489 $ 1,489
SCHEDULE OF FAIR VALUE OF LIABILITY CLASSIFIED COMMON STOCK WARRANTS	The following table presents the change in fair value of the liability classified common stock warrants for the three months ended March 31, 2023 (in thousands): SCHEDULE OF FAIR VALUE OF LIABILITY CLASSIFIED COMMON STOCK WARRANTS Fair Value at December 31, 2022 (Gain) Loss Upon Change in Fair Value Fair Value at March 31, 2023 Warrant liabilities February 14, 2020 issuance $ 8 $ (2 ) $ 6 December 23, 2020 issuance 2 (1 ) 1 January 14, 2021 issuance 72 (42 ) 30 January 25, 2021 issuance 64 (37 ) 27 March 16, 2022 issuance 26 (25 ) 1 June 8, 2022 issuance 1,317 (421 ) 896 Total $ 1,489 $ (528 ) $ 961 The following table presents the change in fair value of the liability classified common stock warrants for the three months ended March 31, 2022 (in thousands): Fair Value at December 31, 2021 Initial Fair Value at Issuance (Gain) Loss Upon Change in Fair Value Fair Value at March 31, 2022 Warrant liabilities February 14, 2020 issuance $ 291 $ – $ (179 ) $ 112 December 23, 2020 issuance 239 – (166 ) 73 January 14, 2021 issuance 3,345 – (1,856 ) 1,489 January 25, 2021 issuance 2,969 – (1,649 ) 1,320 March 16, 2022 issuance – 3,129 (1,255 ) 1,874 Total $ 6,844 $ 3,129 $ (5,105 ) $ 4,868
SCHEDULE OF FAIR VALUE ASSUMPTIONS OF WARRANTS LIABILITY	The Company uses the Monte Carlo simulation model to determine the fair value of the liability classified warrants. Input assumptions used to measure the fair value of these freestanding instruments are as follows: SCHEDULE OF FAIR VALUE ASSUMPTIONS OF WARRANTS LIABILITY For the Three Months ended March 31, 2023 Stock price $ 0.50 0.50 Exercise price $ 2.40 34.38 Risk-free rate 3.68 4.66 % Volatility 107.0 113.1 % Remaining term (years) 0.96 4.19 For the Three Months ended March 31, 2022 Stock price $ 6.25 8.50 Exercise price $ 2.50 34.50 Risk-free rate 1.95 2.44 % Volatility 98.4 103.6 % Remaining term (years) 1.96 4.87

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Mar. 31, 2023
Prepaid Expenses And Other Current Assets
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	The following table presents the major components of prepaid expenses and other current assets (in thousands): SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2023 December 31, 2022 Prepaid insurance $ 1,249 $ 239 Other current receivable 446 332 Prepaid expenses 402 440 Deferred offering costs 98 98 Total prepaid expenses and other current assets $ 2,195 $ 1,109

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT, NET	The following table presents the components of property and equipment, net (in thousands): SCHEDULE OF PROPERTY AND EQUIPMENT, NET March 31, 2023 December 31, 2022 Machinery and equipment $ 4,436 $ 4,436 Computers and software 570 570 Leasehold improvements 1,808 1,808 Furniture and equipment 100 100 Total property and equipment, gross 6,914 6,914 Accumulated depreciation (5,287 ) (5,139 ) Total property and equipment, net $ 1,627 $ 1,775
SCHEDULE OF DEPRECIATION AND AMORTIZATION EXPENSE	Depreciation and amortization expense for property and equipment, including assets acquired under financing leases was as follows (in thousands): SCHEDULE OF DEPRECIATION AND AMORTIZATION EXPENSE For the Three Months Ended March 31, 2023 2022 General and administrative expense $ 3 $ 49 Research and development expense 145 406 Total depreciation and amortization expense $ 148 $ 455

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2023
Leases
SCHEDULE OF OPERATING AND FINANCE LEASE LIABILITIES	As of March 31, 2023, the maturities of operating and finance lease liabilities were as follows (in thousands): SCHEDULE OF OPERATING AND FINANCE LEASE LIABILITIES Operating leases * Finance leases 2023 (excluding the three months ended March 31, 2023) $ 478 $ 45 2024 793 – 2025 781 – 2026 813 – 2027 772 – Total lease payments 3,637 45 Less: Imputed interest (729 ) (1 ) Total $ 2,908 $ 44 * 2023 amounts shown above are net of cash inflows for tenant improvement allowances expected to be received during the year.
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO FINANCE AND OPERATING LEASES	Supplemental balance sheet information related to leases was as follows (in thousands): Finance leases SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO FINANCE AND OPERATING LEASES March 31, 2023 December 31, 2022 Finance lease right-of-use assets included within property and equipment, net $ 4 $ 4 Current finance lease liabilities included within other current liabilities $ 45 $ 293 Non-current finance lease liabilities included within other long-term liabilities – 41 Total $ 45 $ 334 Operating leases March 31, 2023 December 31, 2022 Current operating lease liabilities included within other current liabilities $ 413 $ 394 Operating lease liabilities – non-current 2,495 2,632 Total $ 2,908 $ 3,026
SUMMARY OF COMPONENT OF LEASE EXPENSE	The components of lease expense were as follows (in thousands): SUMMARY OF COMPONENT OF LEASE EXPENSE 2023 2022 For the Three Months Ended March 31, 2023 2022 Operating lease costs included within operating costs and expenses $ 395 $ 318 Finance lease costs: Amortization of right-of-use assets $ – $ 51 Interest on lease liabilities 7 16 Total $ 7 $ 67
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES	Supplemental cash flow information related to leases was as follows (in thousands): SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES 2023 2022 For the Three Months Ended March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash out flows from operating leases $ 192 $ 264 Operating cash out flows from finance leases $ 7 $ 16 Financing cash out flows from finance leases $ 72 $ 116

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES	The following table presents the major components of accounts payable and accrued expenses (in thousands): SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES March 31, 2023 December 31, 2022 Accounts payable $ 244 $ 459 Salaries and other compensation 517 463 Legal and accounting 264 71 Accrued severance 63 16 Benefit plan accrual 66 66 Clinical trials 369 131 Other 191 174 Total accounts payable and accrued expenses $ 1,714 $ 1,380

OTHER CURRENT LIABILITIES (Tabl

OTHER CURRENT LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2023
Other Liabilities Disclosure [Abstract]
SCHEDULE OF OTHER CURRENT LIABILITIES	The following table presents the major components of other current liabilities (in thousands): SCHEDULE OF OTHER CURRENT LIABILITIES March 31, 2023 December 31, 2022 Current finance lease liabilities $ 45 $ 293 Current operating lease liabilities 413 394 Total other current liabilities $ 458 $ 687

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS,ACTIVITY	A summary of the Company’s employee and non-employee stock option activity is presented below: SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS,ACTIVITY Number of Shares Weighted-Average Exercise Price Outstanding – December 31, 2022 182,311 $ 188.50 Granted – $ – Forfeited (21,653 ) $ 163.66 Outstanding – March 31, 2023 160,658 $ 191.85 Options exercisable, March 31, 2023 158,459 $ 193.22
SCHEDULE OF SHARE-BASED COMPENSATION ,RESTRICTED STOCK ACTIVITY	A summary of the Company’s employee and non-employee restricted stock activity is presented below: SCHEDULE OF SHARE-BASED COMPENSATION ,RESTRICTED STOCK ACTIVITY Number of Shares Unvested - December 31, 2022 256,435 Granted 42,986 Vested (66,820 ) Forfeited (38,483 ) Unvested – March 31, 2023 194,118
SCHEDULE OF SHARE-BASED COMPENSATION RELATED TO RESTRICTED STOCK AWARDS AND STOCK OPTIONS	The stock-based compensation expense related to stock options, restricted stock awards, and the employee stock purchase plan was as follows (in thousands): SCHEDULE OF SHARE-BASED COMPENSATION RELATED TO RESTRICTED STOCK AWARDS AND STOCK OPTIONS 2023 2022 For the Three Months Ended March 31, 2023 2022 General and administrative expense $ 31 $ 546 Research and development expense 15 216 Total stock-based compensation expense $ 46 $ 762

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SUMMARY OF WARRANT ACTIVITY	The following table summarizes warrant activity for the three months ended March 31, 2023: SUMMARY OF WARRANT ACTIVITY Outstanding December 31, 2022 Warrants Issued Warrants Exercised Outstanding March 31, 2023 Transaction February 14, 2020 common warrants 21,580 – – 21,580 December 23, 2020 placement agent warrants 25,651 – – 25,651 January 14, 2021 common warrants 363,636 – – 363,636 January 14, 2021 placement agent warrants 21,818 – – 21,818 January 25, 2021 common warrants 320,641 – – 320,641 January 22, 2021 placement agent warrants 19,238 – – 19,238 March 16, 2022 common warrants 655,738 – – 655,738 March 16, 2022 placement agent warrants 32,787 – – 32,787 June 8, 2022 common warrants 3,168,318 – – 3,168,318 June 8, 2022 placement agent warrants 158,416 – – 158,416 Total 4,787,823 – – 4,787,823

NET LOSS PER SHARE ATTRIBUTAB_2

NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS (Tables)	3 Months Ended
	Mar. 31, 2023
Net loss per share attributable to common stockholders
SCHEDULE OF EARNINGS PER SHARE , BASIC AND DILUTED	The following tables present reconciliations for the numerators and denominators of basic and diluted net loss per share: SCHEDULE OF EARNINGS PER SHARE , BASIC AND DILUTED Numerator: 2023 2022 For the Three Months Ended March 31, March 31, Numerator: 2023 2022 Net loss, primary $ (4,243 ) $ (3,771 ) Less: gain from change in fair value of warrant liabilities – (4,694 ) Net loss, diluted $ (4,243 ) $ (8,465 ) Denominator: 2023 2022 For the Three Months Ended March 31, March 31, Denominator: 2023 2022 Basic weighted average number of common shares 7,320,754 3,364,535 Potentially dilutive effect of warrants – 211,435 Diluted weighted average number of common shares 7,320,754 3,575,970
SCHEDULE OF ANTI-DILUTIVE POTENTIAL SHARES OUTSTANDING ACTIVITY	The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share for the periods presented due to their anti-dilutive effect: SCHEDULE OF ANTI-DILUTIVE POTENTIAL SHARES OUTSTANDING ACTIVITY 2023 2022 For the Three Months Ended March 31, March 31, 2023 2022 Stock options 160,658 212,428 Restricted stock 194,118 174,054 Common stock warrants 4,787,823 66,708 Shares committed under ESPP 5,584 1,923 Outstanding potentially dilutive securities 5,584 1,923

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
SCHEDULE OF SEGMENT INFORMATION	Certain information concerning the Company’s segments is presented in the following tables (in thousands): SCHEDULE OF SEGMENT INFORMATION 2023 2022 For the Three Months Ended March 31, 2023 2022 Net revenues: Reportable segments: Regenerative medicine $ — $ — Contract services — 741 Total net revenues $ — $ 741 Net (loss)/income: Reportable segments: Regenerative medicine $ (4,243 ) $ (3,545 ) Contract services — (226 ) Total net loss $ (4,243 ) $ (3,771 )

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)			3 Months Ended
	May 16, 2022	May 12, 2022	Mar. 31, 2023	Jun. 08, 2022	Mar. 16, 2022
Insurance limit			$ 250,000
assets held for sale and recorded an impairment loss			$ 100,000
Stockholders equity reverse stock split	1-for-25	1-for-25 (“Reverse Stock Split”)
Stock issued during period shares reverse stock split		17,024
Class of warrant right exercise price					$ 8.75
Pre-funded Warrants [Member]
Class of warrant right exercise price			$ 0.025	$ 3.156

LIQUIDITY AND GOING CONCERN (De

LIQUIDITY AND GOING CONCERN (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 520,474	$ 516,231
Cash and cash equivalents	$ 6,394	$ 11,446

SCHEDULE OF FAIR VALUE OF FINAN

SCHEDULE OF FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES MEASURES ON RECURRING BASIS (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value	$ 961	$ 1,489
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value	961	1,489
Common Stock Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value	961	1,489
Common Stock Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value
Common Stock Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value
Common Stock Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total liabilities, fair value	$ 961	$ 1,489

SCHEDULE OF FAIR VALUE OF LIABI

SCHEDULE OF FAIR VALUE OF LIABILITY CLASSIFIED COMMON STOCK WARRANTS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value, beginning	$ 1,489	$ 6,844
(Gain) loss upon change in fair value	(528)	(5,105)
Fair value, ending	961	4,868
Initial fair value issuance		3,129
February 14, 2020 Issuance [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value, beginning	8	291
(Gain) loss upon change in fair value	(2)	(179)
Fair value, ending	6	112
Initial fair value issuance
December 23, 2020 Warrants [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value, beginning	2	239
(Gain) loss upon change in fair value	(1)	(166)
Fair value, ending	1	73
Initial fair value issuance
January 14, 2021 Issuance [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value, beginning	72	3,345
(Gain) loss upon change in fair value	(42)	(1,856)
Fair value, ending	30	1,489
Initial fair value issuance
January 25, 2021 Issuance [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value, beginning	64	2,969
(Gain) loss upon change in fair value	(37)	(1,649)
Fair value, ending	27	1,320
Initial fair value issuance
March 16, 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value, beginning	26
(Gain) loss upon change in fair value	(25)	(1,255)
Fair value, ending	1	1,874
Initial fair value issuance		$ 3,129
June 08 ,2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value, beginning	1,317
(Gain) loss upon change in fair value	(421)
Fair value, ending	$ 896

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS OF WARRANTS LIABILITY (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price			$ 2.40
Minimum [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price	$ 0.50	$ 6.25
Minimum [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price	$ 2.40	$ 2.50
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free rate	3.68%	1.95%
Minimum [Member] | Measurement Input, Option Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Volatility	107%	98.40%
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining term (years)	11 months 15 days	1 year 11 months 15 days
Maximum [Member] | Measurement Input, Share Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock price	$ 0.50	$ 8.50
Maximum [Member] | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise price	$ 34.38	$ 34.50
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Risk-free rate	4.66%	2.44%
Maximum [Member] | Measurement Input, Option Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Volatility	113.10%	103.60%
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Remaining term (years)	4 years 2 months 8 days	4 years 10 months 13 days

FAIR VALUE (Details Narrative)

FAIR VALUE (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Definite-lived intangible assets	$ 56	$ 54

ASSETS AND LIABILITIES HELD F_2

ASSETS AND LIABILITIES HELD FOR SALE (Details Narrative) $ in Thousands			3 Months Ended
	Apr. 29, 2022 USD ($)	Apr. 14, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Nov. 30, 2022 ft²	May 31, 2018 a
Impairment of assets held for sale			$ 56	$ 54
Area of land | ft²						63,156
Other assets non current			$ 911		$ 911
Stock Agreement [Member]
Debt, principal amount		$ 400
Debt interest rate		10%
Debt instrument interest terms		five-year
Real Estate Agreement [Member]
Business combination consideration		$ 2,800
Stock agreement and real estate agreement [Member]
Other assets non current	$ 400
Issuance of debt	2,300
Long term note receivable	$ 400
IBEX Property LLC [Member] | UTAH
Area of land | a							1.75

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Prepaid insurance	$ 1,249	$ 239
Other current receivable	446	332
Prepaid expenses	402	440
Deferred offering costs	98	98
Total prepaid expenses and other current assets	$ 2,195	$ 1,109

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Machinery and equipment	$ 4,436	$ 4,436
Computers and software	570	570
Leasehold improvements	1,808	1,808
Furniture and equipment	100	100
Total property and equipment, gross	6,914	6,914
Accumulated depreciation	(5,287)	(5,139)
Total property and equipment, net	$ 1,627	$ 1,775

SCHEDULE OF DEPRECIATION AND AM

SCHEDULE OF DEPRECIATION AND AMORTIZATION EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Total depreciation and amortization expense	$ 148	$ 455
General and Administrative Expense [Member]
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Total depreciation and amortization expense	3	49
Research and Development Expense [Member]
Impaired Assets to be Disposed of by Method Other than Sale [Line Items]
Total depreciation and amortization expense	$ 145	$ 406

SCHEDULE OF OPERATING AND FINAN

SCHEDULE OF OPERATING AND FINANCE LEASE LIABILITIES (Details) - USD ($) $ in Thousands		Mar. 31, 2023		Dec. 31, 2022
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Operating leases 2023	[1]	$ 478
Operating leases 2024	[1]	793
Operating leases 2025	[1]	781
Operating leases 2026	[1]	813
Operating leases 2027	[1]	772
Total Operating lease payments	[1]	3,637
Less: Operating leases Imputed interest	[1]	(729)
Total Operating leases		2,908	[1]	$ 3,026
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Finance leases 2023		45
Finance leases 2024
Finance leases 2025
Finance leases 2026
Finance leases 2027
Total Finance lease payments		45
Less: Finance leases Imputed interest		(1)
Total Finance leases		$ 44
[1]2023 amounts shown above are net of cash inflows for tenant improvement allowances expected to be received during the year.

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO FINANCE AND OPERATING LEASES (Details) - USD ($) $ in Thousands	Mar. 31, 2023		Dec. 31, 2022
Leases
Finance lease right-of-use assets included within property and equipment, net	$ 4		$ 4
Current finance lease liabilities included within other current liabilities	45		293
Non-current finance lease liabilities included within other long-term liabilities			41
Total	45		334
Current operating lease liabilities included within other current liabilities	413		394
Operating lease liabilities – non-current	2,495		2,632
Total Operating leases	$ 2,908	[1]	$ 3,026
[1]2023 amounts shown above are net of cash inflows for tenant improvement allowances expected to be received during the year.

SUMMARY OF COMPONENT OF LEASE E

SUMMARY OF COMPONENT OF LEASE EXPENSE (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases
Operating lease costs included within operating costs and expenses	$ 395	$ 318
Amortization of right-of-use assets		51
Interest on lease liabilities	7	16
Total	$ 7	$ 67

SCHEDULE OF SUPPLEMENTAL CASH F

SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases
Operating cash out flows from operating leases	$ 192	$ 264
Operating cash out flows from finance leases	7	16
Financing cash out flows from finance leases	$ 72	$ 116

LEASES (Details Narrative)

LEASES (Details Narrative)	1 Months Ended		3 Months Ended
	Nov. 30, 2022 USD ($) ft²	Nov. 30, 2021 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022
Area of land | ft²	63,156
Lease renewal description	The initial term of the lease is five years, and it expires on November 30, 2027
Lease term	5 years
Lease expiration date	Nov. 30, 2027
Lease renewal description	The Company has a one-time option to renew for an additional five years
Rent description	The initial base rent under this lease is $59,998 per month ($0.95 per sq. ft.) for the first year of the initial lease term and increases 4.0% per annum thereafter
Base rental	$ 59,998
Increase in rental rate	4%
Operating lease incremental borrowing rate	10%
Financing lease, incremental borrowing rate			10%
Abandonment finance lease right of use asset			$ 200,000
gain on termination of the lease			$ 61,000
Operating lease, weighted average remaining lease term			4 years 7 months 6 days		4 years 9 months 18 days
Operating lease, weighted average discount rate, percent			9.70%		9.69%
Finance lease, weighted average remaining lease term			8 months 12 days		1 year 2 months 12 days
Finance lease, weighted average discount rate, percent			8.25%		9.67%
Minimum [Member]
Lessee, operating lease, remaining lease term			3 months
Maximum [Member]
Lessee, operating lease, remaining lease term			8 months
Pacific Office Automation Inc [Member]
Lease term		3 years
Rent description		The initial base rent under this lease is $3,983 per month for the entire lease term and includes a cash incentive of $0.1 million
Base rental		$ 3,983
Operating lease incremental borrowing rate		7.42%
Incentive fee		$ 100,000

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable	$ 244	$ 459
Salaries and other compensation	517	463
Legal and accounting	264	71
Accrued severance	63	16
Benefit plan accrual	66	66
Clinical trials	369	131
Other	191	174
Total accounts payable and accrued expenses	$ 1,714	$ 1,380

SCHEDULE OF OTHER CURRENT LIABI

SCHEDULE OF OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Other Liabilities Disclosure [Abstract]
Current finance lease liabilities	$ 45	$ 293
Current operating lease liabilities	413	394
Total other current liabilities	$ 458	$ 687

SCHEDULE OF SHARE-BASED COMPENS

SCHEDULE OF SHARE-BASED COMPENSATION, STOCK OPTIONS,ACTIVITY (Details) - Employee and Non Employee Stock Option [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Number of Shares, Outstanding at beginning of period | shares	182,311
Weighted Average Exercise Price, Outstanding at beginning of period | $ / shares	$ 188.50
Number of Shares, Granted | shares
Weighted Average Exercise Price, Granted | $ / shares
Number of Shares, Forfeited | shares	(21,653)
Weighted Average Exercise Price, Forfeited | $ / shares	$ 163.66
Number of Shares, Outstanding at end of period | shares	160,658
Weighted Average Exercise Price, Outstanding at end of period | $ / shares	$ 191.85
Number of Shares, Options exercisable | shares	158,459
Weighted Average Exercise Price, Options exercisable | $ / shares	$ 193.22

SCHEDULE OF SHARE-BASED COMPE_2

SCHEDULE OF SHARE-BASED COMPENSATION ,RESTRICTED STOCK ACTIVITY (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares, Unvested at beginning of period	256,435
Number of Shares, Granted	42,986
Number of Shares, Vested	(66,820)
Number of Shares, Forfeited	(38,483)
Number of Shares, Unvested at end of period	194,118

SCHEDULE OF SHARE-BASED COMPE_3

SCHEDULE OF SHARE-BASED COMPENSATION RELATED TO RESTRICTED STOCK AWARDS AND STOCK OPTIONS (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 46	$ 762
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	31	546
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 15	$ 216

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - shares				1 Months Ended	3 Months Ended
	Oct. 25, 2019	Oct. 05, 2018	Dec. 01, 2016	May 31, 2018	Mar. 31, 2023	Sep. 09, 2022	Jan. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Available for future issuances ESPP					5,584
2020 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation terminate date	Dec. 19, 2029
Number of shares reserved					6,357	1,450,000	131,872
2020 Equity Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock issuable	419,549
2019 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation terminate date		Oct. 05, 2028
Number of shares reserved					10,920
2019 Equity Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock issuable		120,000
2017 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock based compensation terminate date			Dec. 01, 2026
Number of shares reserved					14,246
2017 Equity Incentive Plan [Member] | Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock issuable			292,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares reserved				20,000
Common stock purchase price percentage				85%

SUMMARY OF WARRANT ACTIVITY (De

SUMMARY OF WARRANT ACTIVITY (Details)	3 Months Ended
	Mar. 31, 2023 shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	4,787,823
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	4,787,823
February 14, 2020 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	21,580
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	21,580
December 23, 2020 placement agent warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	25,651
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	25,651
January 14, 2021 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	363,636
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	363,636
January 14, 2021 Placement Agent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	21,818
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	21,818
January 25, 2021 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	320,641
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	320,641
January 22, 2021 Placement Agent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	19,238
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	19,238
March 16, 2022 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	655,738
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	655,738
March 16, 2022 Placement Agent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	32,787
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	32,787
June 8, 2022 Common Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	3,168,318
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	3,168,318
June 8, 2022 Placement Agent Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant outstanding, beginning balance	158,416
Warrants Issued
Warrants exercised
Warrant outstanding, ending balance	158,416

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

15 Months Ended

Jun. 08, 2022

Mar. 29, 2022

Mar. 17, 2022

Mar. 16, 2022

Mar. 30, 2021

Aug. 31, 2022

Jul. 31, 2022

Jun. 30, 2022

Mar. 31, 2022

Mar. 31, 2023

Mar. 31, 2023

Dec. 31, 2022

Feb. 28, 2022

Jan. 25, 2021

Jan. 14, 2021

Class of Stock [Line Items]

Preferred stock shares issued

0

0

0

Common stock and warrants purchase shares

655,738

Number of shares issued

$ 5,000

Class of warrant right exercise price

$ 8.75

Conversion price

$ 7.625

Common stock, par or stated value per share

$ 0.001

$ 0.001

$ 0.001

Exercise price

$ 2.40

Deferred offering costs

$ 98

$ 98

$ 98

Sales Agreement [Member]

Class of Stock [Line Items]

Proceeds from issuance of common stock

$ 50,000

Investment

$ 400

Deferred offering costs

$ 700

Private Placement [Member]

Class of Stock [Line Items]

Fair value adjustment of warrants

100

Proceeds from exercise of warrants

7,300

Noninterest expense offering cost

$ 700

IPO [Member]

Class of Stock [Line Items]

Class of warrant right exercise price

$ 2.524

Number of shares issued

445,500

Public offering price per share

$ 2.525

Common stock, par or stated value per share

$ 0.001

Maximum [Member]

Class of Stock [Line Items]

Class of warrant right exercise price

$ 30

Maximum [Member] | Private Placement [Member]

Class of Stock [Line Items]

Common stock and warrants purchase shares

158,416

3,168,318

Percentage of warrant exercise price

125%

Minimum [Member]

Class of Stock [Line Items]

Class of warrant right exercise price

$ 8.75

Common Stock [Member]

Class of Stock [Line Items]

Common stock and warrants purchase shares

655,738

Number of shares issued

$ 1,000,000

Fair value adjustment of warrants

$ 2,000

Number of shares issued

1,689,159

545,000

488,659

3,168,318

Warrant [Member]

Class of Stock [Line Items]

Common stock and warrants purchase shares

320,641

363,636

Fair value adjustment of warrants

3,000

Proceeds from exercise of warrants

4,500

Noninterest expense offering cost

$ 300

Warrants [Member]

Class of Stock [Line Items]

Warrant forIssuing to nonemployees

The holder of the warrants may not exercise any portion of such warrants to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, which percentage may be changed at the holder’s election to a lower percentage at any time or to a higher percentage not to exceed 9.99% upon 61 days’ notice to the Company. The Company also issued to designees of the placement agent, warrants to purchase 5.0% of the aggregate number of common stock shares and pre-funded warrants sold in the offering

The holder of the March 2022 Warrants may not exercise any portion of such warrants to the extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, which percentage may be changed at the holder’s election to a lower percentage at any time or to a higher percentage not to exceed 9.99% upon 61 days’ notice to the Company

Placement Agent Common Stock Warrants [Member]

Class of Stock [Line Items]

Common stock and warrants purchase shares

32,787

Price per share

$ 0.050

Fair value adjustment of warrants

$ 300

Series A and Series B Preferred Stock [Member]

Class of Stock [Line Items]

Residual value of warrants and stock offering

$ 1,900

Preferred Stock [Member]

Class of Stock [Line Items]

Proceeds from exercise of warrants

$ 200

Pre Funded Warrant [Member]

Class of Stock [Line Items]

Common stock and warrants purchase shares

1,584,159

Class of warrant right exercise price

$ 2.524

Pre Funded Warrant [Member] | IPO [Member]

Class of Stock [Line Items]

Common stock and warrants purchase shares

1,138,659

Class of warrant right exercise price

$ 0.001

Pre-funded Warrants [Member]

Class of Stock [Line Items]

Class of warrant right exercise price

$ 3.156

$ 0.025

$ 0.025

Common Stock Warrants [Member]

Class of Stock [Line Items]

Fair value adjustment of warrants

$ 5,700

Additional Paid-in Capital [Member]

Class of Stock [Line Items]

Fair value adjustment of warrants

200

Classified Warrants [Member]

Class of Stock [Line Items]

Fair value adjustment of warrants

$ 500

Series A Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock shares issued

3,000.000435

Series B Convertible Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock shares issued

2,000.00029

Series B Preferred Stock [Member]

Class of Stock [Line Items]

Conversion of stock shares converted

262,295

Series A Preferred Stock [Member]

Class of Stock [Line Items]

Conversion of stock shares converted

393,443

Series A and Series B Preferred Stock [Member]

Class of Stock [Line Items]

Class of warrant right exercise price

$ 9.525

Percentage of exercise of warrants

125%

SCHEDULE OF EARNINGS PER SHARE

SCHEDULE OF EARNINGS PER SHARE , BASIC AND DILUTED (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net loss per share attributable to common stockholders
Net loss, primary	$ (4,243)	$ (3,771)
Less: gain from change in fair value of warrant liabilities		(4,694)
Net loss, diluted	$ (4,243)	$ (8,465)
Basic weighted average number of common shares	7,320,754	3,364,535	[1]
Potentially dilutive effect of warrants		211,435,000
Diluted weighted average number of common shares	7,320,754	3,575,970	[1]
[1]Giving retroactive effect to the 1-for-25

SCHEDULE OF ANTI-DILUTIVE POTEN

SCHEDULE OF ANTI-DILUTIVE POTENTIAL SHARES OUTSTANDING ACTIVITY (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding potentially dilutive securities	160,658	212,428
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding potentially dilutive securities	194,118	174,054
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding potentially dilutive securities	4,787,823	66,708
Shares Committed Under ESPP [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding potentially dilutive securities	5,584	1,923

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	Jun. 25, 2021	Jul. 31, 2021	Mar. 31, 2023	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Research and development cost	$ 6,500		$ 2,282	$ 2,860
Service fees	3,100
Estimated cost	$ 3,400
Recited costs		$ 500
Costs and expenses			$ 400	$ 200

SCHEDULE OF SEGMENT INFORMATION

SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Total net revenues		$ 741
Total net loss	(4,243)	(3,771)
Regenerative Medicine [Member]
Segment Reporting Information [Line Items]
Total net revenues
Total net loss	(4,243)	(3,545)
Contract Services [Member]
Segment Reporting Information [Line Items]
Total net revenues		741
Total net loss		$ (226)